News

• FDA approves generic teriparatide and levetiracetam
• US generics launch and approval for Dr Reddy’s and Lupin
• Five Chinese companies join UN’s MPP for Covid-19 medicines
• South Korean companies to make generic Bridion and COVID-19 drugs

Research

• Japan’s drug shortage crisis: challenges and policy solutions
• Saudi FDA drug approvals and GMP inspections: trend analysis
• Generic medications in the Lebanese community: understanding and public perception
• Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study

General

• Generic drug growth in Brazil and Venezuela
• Market penetration of generic drugs in Mexico and Brazil
• FDA releases one-year progress report for the Generic Drug Cluster
• Pharmaceutical manufacturing companies in Brazil

News

• FDA approves fifth ustekinumab biosimilar Imuldosa
• EC approval for three ustekinumab biosimilar: Eksunbi, Fymskina, Otulfi
• FDA approves biosimilars: ustekinumab Otulfi and eculizumab Epysqli
• FDA approves second strength of trastuzumab biosimilar Hercessi

Research

• Long-term real-world safety experience of biosimilars confirms concept of biosimilarity
• Budget impact analysis of Rixathon introduction in Chile for non-Hodgkin lymphoma
• Biosimilars in inflammatory bowel disease: are we ready for multiple switches
• Topline results from clinical development programme for candidate biosimilar AVT05 golimumab

General

• SBR issues consensus on interchangeability of reference products and biosimilars
• Innovative direct purchase agreement sees adalimumab biosimilar prices slashed
• Stelara biosimilar available at US$0 for Accredo patients
• Ten best-selling biosimilars in Brazil in 2023

• Latin American Forum
• Non‐Biological Complex Drugs
• Country Focus

• Guidelines
• Policies & Legislation
• Reports

• Conferences
• Sponsored Articles
• Sponsored Links